WO2002043760A1 - Saccharometabolism activators - Google Patents

Saccharometabolism activators Download PDF

Info

Publication number
WO2002043760A1
WO2002043760A1 PCT/JP2001/010463 JP0110463W WO0243760A1 WO 2002043760 A1 WO2002043760 A1 WO 2002043760A1 JP 0110463 W JP0110463 W JP 0110463W WO 0243760 A1 WO0243760 A1 WO 0243760A1
Authority
WO
WIPO (PCT)
Prior art keywords
saccharometabolism
erk
phosphorylation
pathway
insulin
Prior art date
Application number
PCT/JP2001/010463
Other languages
French (fr)
Japanese (ja)
Inventor
Junji Ichihara
Mutsuo Taiji
Hironori Ishikawa
Fumiyo Hirota
Original Assignee
Sumitomo Pharmaceuticals Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharmaceuticals Co., Ltd. filed Critical Sumitomo Pharmaceuticals Co., Ltd.
Priority to AU2002224126A priority Critical patent/AU2002224126A1/en
Priority to JP2002545730A priority patent/JPWO2002043760A1/en
Publication of WO2002043760A1 publication Critical patent/WO2002043760A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A method of improving and strengthening saccharometabolism characterized by inhibiting the phosphorylation of ERK in the insulin signal transfer pathway; an ERK phosphorylation inhibitor; a glycogen synthesis promoter; a method of screening the same; and saccharometabolism activators and remedies for saccharometabolism-associated diseases containing the same. By altering the cross talk balance in the insulin signal transfer pathway (i.e., inhibiting the phosphorylation of ERK located in the MAPK pathway), the saccharometabolism activity of insulin based on the PI3K pathway, which is another signal transfer pathway, can be strengthened. Therefore, a compound inhibiting the phosphorylation of ERK can be used as a saccharometabolism-improving agent, in particular, a drug efficacious against insulin resistant diabetes or life style-related diseases.
PCT/JP2001/010463 2000-12-01 2001-11-30 Saccharometabolism activators WO2002043760A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002224126A AU2002224126A1 (en) 2000-12-01 2001-11-30 Saccharometabolism activators
JP2002545730A JPWO2002043760A1 (en) 2000-12-01 2001-11-30 Sugar metabolism activator

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000367838 2000-12-01
JP2000-367838 2000-12-01

Publications (1)

Publication Number Publication Date
WO2002043760A1 true WO2002043760A1 (en) 2002-06-06

Family

ID=18838191

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/010463 WO2002043760A1 (en) 2000-12-01 2001-11-30 Saccharometabolism activators

Country Status (3)

Country Link
JP (1) JPWO2002043760A1 (en)
AU (1) AU2002224126A1 (en)
WO (1) WO2002043760A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006509795A (en) * 2002-12-12 2006-03-23 ノバルティス アクチエンゲゼルシャフト Methods for treating symptoms associated with dysregulation of insulin signaling
US8933239B1 (en) 2013-07-16 2015-01-13 Dow Global Technologies Llc Bis(aryl)acetal compounds
US8962779B2 (en) 2013-07-16 2015-02-24 Dow Global Technologies Llc Method of forming polyaryl polymers
US9063420B2 (en) 2013-07-16 2015-06-23 Rohm And Haas Electronic Materials Llc Photoresist composition, coated substrate, and method of forming electronic device
US9410016B2 (en) 2013-07-16 2016-08-09 Dow Global Technologies Llc Aromatic polyacetals and articles comprising them

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996003148A1 (en) * 1994-07-27 1996-02-08 Ono Pharmaceutical Co., Ltd. Method and drug for treating diabetes
WO2001036386A1 (en) * 1999-11-17 2001-05-25 Sumitomo Pharmaceuticals Co., Ltd. Diabetic remedy containing dipiperazine derivative
JP2001199901A (en) * 2000-01-21 2001-07-24 Sumitomo Pharmaceut Co Ltd Myosin agonist

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996003148A1 (en) * 1994-07-27 1996-02-08 Ono Pharmaceutical Co., Ltd. Method and drug for treating diabetes
WO2001036386A1 (en) * 1999-11-17 2001-05-25 Sumitomo Pharmaceuticals Co., Ltd. Diabetic remedy containing dipiperazine derivative
JP2001199901A (en) * 2000-01-21 2001-07-24 Sumitomo Pharmaceut Co Ltd Myosin agonist

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KEIJI ISSHIKI ET AL.: "Kakushu byoutai to insulin teikou-sei-thiazolidine yudou-tai no rinshou ouyou no tenbou, jin-shikkan", NIPPON RINSHOU, vol. 58, no. 2, February 2000 (2000-02-01), pages 166 - 171, XP002909064 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006509795A (en) * 2002-12-12 2006-03-23 ノバルティス アクチエンゲゼルシャフト Methods for treating symptoms associated with dysregulation of insulin signaling
US8933239B1 (en) 2013-07-16 2015-01-13 Dow Global Technologies Llc Bis(aryl)acetal compounds
US8962779B2 (en) 2013-07-16 2015-02-24 Dow Global Technologies Llc Method of forming polyaryl polymers
US9063420B2 (en) 2013-07-16 2015-06-23 Rohm And Haas Electronic Materials Llc Photoresist composition, coated substrate, and method of forming electronic device
US9410016B2 (en) 2013-07-16 2016-08-09 Dow Global Technologies Llc Aromatic polyacetals and articles comprising them

Also Published As

Publication number Publication date
AU2002224126A1 (en) 2002-06-11
JPWO2002043760A1 (en) 2004-04-02

Similar Documents

Publication Publication Date Title
Taubert et al. Impact of P‐glycoprotein on clopidogrel absorption
Yun et al. Inhibitory effects of green tea polyphenol (–)‐epigallocatechin gallate on the expression of matrix metalloproteinase‐9 and on the formation of osteoclasts
WO2003011851A3 (en) Aromatic hydroxamic acid derivatives useful as hdac inhibitors
EP1559710A3 (en) Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV, process for their preparation and their use
HUP0102250A2 (en) Compounds of unstable dipeptidyl peptidase iv inhibitors, pharmaceutical compositions comprising thereof and their use
Belorgey et al. 1, 4-naphthoquinones and other NADPH-dependent glutathione reductase-catalyzed redox cyclers as antimalarial agents
WO2000038666A3 (en) A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES
WO2002086107A3 (en) A method for differentiating stem cells into insulin-producing cells
NO20042161L (en) Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1
WO2002094203A3 (en) Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
BG105431A (en) METHOD FOR TREATING DIABETES EMPLOYING AN Ap2 INHIBITOR AND COMBINATION
EP1214945A3 (en) Method and medicament for inhibiting the expression of a defined gene
CY1111835T1 (en) Late Release Disk Tab
MY120064A (en) Indole derivatives as inhibitors or factor xa
WO2000059506A8 (en) HETEROCYCLIC CONTAINING BIPHENYL aP2 INHIBITORS AND METHOD
GEP20033028B (en) Heterocyclic Compounds as Inhibitors of Rotamase Enzymes, Method for Their Production, Pharmaceutical Composition Containing Them and Use Thereof
WO2003042185A1 (en) Xanthine oxidase inhibitors
WO2004037789A3 (en) Methylene urea derivatives as raf-kinase inhibitors
EP1295609A4 (en) Drugs containing combined active ingredients
Assfalg-Machleidt et al. Enzymatically active cathepsin B dissociating from its inhibitor complexes is elevated in blood plasma of patients with septic shock and some malignant tumors.
WO2002043760A1 (en) Saccharometabolism activators
EP1749812A4 (en) Polymerization inhibitor, composition containing the same and process for producing easily polymerizable compound with the polymerization inhibitor
MXPA04006802A (en) Pheny(alkyl)carboxylic acid derivatives and dionic phenylalkylheterocyclic derivatives and their use as medicines with serum glucose and/or serum lipid lowering activity.
WO2004013348A3 (en) Method for determining endoglycosidase enzyme activity
MXPA03004209A (en) Pharmaceutical or cosmetic composition and use of a pkc inhibitor with an mmp inhibitor for inhibiting langerhans cell migration.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002545730

Country of ref document: JP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase